CYCCP Cyclacel Pharmaceuticals, Inc.


$ 5.04 $ -0.23 (-4.36 %)    

Thursday, 11-Sep-2025 15:01:44 EDT
QQQ $ 611.00 $ -6.68 (-1.08 %)
DIA $ 478.76 $ -2.60 (-0.54 %)
SPY $ 675.46 $ -4.97 (-0.74 %)
TLT $ 89.78 $ -0.02 (-0.02 %)
GLD $ 386.97 $ -0.32 (-0.08 %)
$ 5.05
$ 5.35
$ 4.70 x 425
$ 5.70 x 200
-- - --
$ 3.10 - $ 16.00
6,463
na
3.22M
$ 0.48
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company"))), a biopharmaceutical ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company"))) today announced that ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ:CYCC, NASDAQ:CYCCP), a biopharmaceutical company that develops inno...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmace...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmace...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles

 - Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action -BERKELEY HEIGH...

Core News & Articles

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study i...

Core News & Articles

- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program ...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

Core News & Articles

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )))), a biopharmac...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION